nodes	percent_of_prediction	percent_of_DWPC	metapath
Mefenamic acid—AKR1C3—Podofilox—Teniposide—lymphatic system cancer	0.0216	0.71	CbGdCrCtD
Mefenamic acid—AKR1C3—Vinblastine—Vincristine—lymphatic system cancer	0.00884	0.29	CbGdCrCtD
Mefenamic acid—Stomatitis—Mitoxantrone—lymphatic system cancer	0.00215	0.00222	CcSEcCtD
Mefenamic acid—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.00214	0.00221	CcSEcCtD
Mefenamic acid—Haemoglobin—Carmustine—lymphatic system cancer	0.00214	0.00221	CcSEcCtD
Mefenamic acid—Urticaria—Teniposide—lymphatic system cancer	0.00214	0.0022	CcSEcCtD
Mefenamic acid—Oliguria—Methotrexate—lymphatic system cancer	0.00213	0.0022	CcSEcCtD
Mefenamic acid—Glossitis—Methotrexate—lymphatic system cancer	0.00213	0.0022	CcSEcCtD
Mefenamic acid—Haemorrhage—Carmustine—lymphatic system cancer	0.00213	0.0022	CcSEcCtD
Mefenamic acid—Abdominal pain—Teniposide—lymphatic system cancer	0.00213	0.00219	CcSEcCtD
Mefenamic acid—Body temperature increased—Teniposide—lymphatic system cancer	0.00213	0.00219	CcSEcCtD
Mefenamic acid—Paraesthesia—Fludarabine—lymphatic system cancer	0.00212	0.00219	CcSEcCtD
Mefenamic acid—Hallucination—Carmustine—lymphatic system cancer	0.00212	0.00219	CcSEcCtD
Mefenamic acid—Dyspnoea—Fludarabine—lymphatic system cancer	0.00211	0.00217	CcSEcCtD
Mefenamic acid—Haematuria—Mitoxantrone—lymphatic system cancer	0.0021	0.00217	CcSEcCtD
Mefenamic acid—Dyspepsia—Fludarabine—lymphatic system cancer	0.00208	0.00215	CcSEcCtD
Mefenamic acid—Hepatic enzyme increased—Methotrexate—lymphatic system cancer	0.00208	0.00214	CcSEcCtD
Mefenamic acid—Ulcer—Methotrexate—lymphatic system cancer	0.00208	0.00214	CcSEcCtD
Mefenamic acid—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00206	0.00212	CcSEcCtD
Mefenamic acid—Decreased appetite—Fludarabine—lymphatic system cancer	0.00206	0.00212	CcSEcCtD
Mefenamic acid—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00204	0.00211	CcSEcCtD
Mefenamic acid—Hallucination—Vincristine—lymphatic system cancer	0.00202	0.00209	CcSEcCtD
Mefenamic acid—Constipation—Fludarabine—lymphatic system cancer	0.00202	0.00209	CcSEcCtD
Mefenamic acid—Vasculitis—Methotrexate—lymphatic system cancer	0.00201	0.00208	CcSEcCtD
Mefenamic acid—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00201	0.00207	CcSEcCtD
Mefenamic acid—Urethral disorder—Vincristine—lymphatic system cancer	0.00199	0.00206	CcSEcCtD
Mefenamic acid—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00199	0.00205	CcSEcCtD
Mefenamic acid—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00198	0.00204	CcSEcCtD
Mefenamic acid—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00198	0.00204	CcSEcCtD
Mefenamic acid—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00197	0.00203	CcSEcCtD
Mefenamic acid—Anaemia—Bleomycin—lymphatic system cancer	0.00196	0.00202	CcSEcCtD
Mefenamic acid—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00195	0.00201	CcSEcCtD
Mefenamic acid—Asthenia—Teniposide—lymphatic system cancer	0.00193	0.00199	CcSEcCtD
Mefenamic acid—Melaena—Methotrexate—lymphatic system cancer	0.00192	0.00198	CcSEcCtD
Mefenamic acid—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.00192	0.00198	CcSEcCtD
Mefenamic acid—Malaise—Bleomycin—lymphatic system cancer	0.00192	0.00198	CcSEcCtD
Mefenamic acid—Pruritus—Teniposide—lymphatic system cancer	0.0019	0.00196	CcSEcCtD
Mefenamic acid—Arrhythmia—Carmustine—lymphatic system cancer	0.0019	0.00196	CcSEcCtD
Mefenamic acid—Leukopenia—Bleomycin—lymphatic system cancer	0.0019	0.00196	CcSEcCtD
Mefenamic acid—Cystitis—Methotrexate—lymphatic system cancer	0.0019	0.00196	CcSEcCtD
Mefenamic acid—Alopecia—Carmustine—lymphatic system cancer	0.00188	0.00194	CcSEcCtD
Mefenamic acid—Body temperature increased—Fludarabine—lymphatic system cancer	0.00187	0.00193	CcSEcCtD
Mefenamic acid—Mental disorder—Carmustine—lymphatic system cancer	0.00187	0.00192	CcSEcCtD
Mefenamic acid—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.00184	0.0019	CcSEcCtD
Mefenamic acid—Diarrhoea—Teniposide—lymphatic system cancer	0.00184	0.0019	CcSEcCtD
Mefenamic acid—Alopecia—Vincristine—lymphatic system cancer	0.0018	0.00185	CcSEcCtD
Mefenamic acid—Coma—Methotrexate—lymphatic system cancer	0.0018	0.00185	CcSEcCtD
Mefenamic acid—Discomfort—Bleomycin—lymphatic system cancer	0.00179	0.00184	CcSEcCtD
Mefenamic acid—Mental disorder—Vincristine—lymphatic system cancer	0.00178	0.00184	CcSEcCtD
Mefenamic acid—Ecchymosis—Methotrexate—lymphatic system cancer	0.00178	0.00183	CcSEcCtD
Mefenamic acid—Urine output increased—Methotrexate—lymphatic system cancer	0.00178	0.00183	CcSEcCtD
Mefenamic acid—Bladder pain—Methotrexate—lymphatic system cancer	0.00178	0.00183	CcSEcCtD
Mefenamic acid—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00177	0.00182	CcSEcCtD
Mefenamic acid—Alopecia—Mitoxantrone—lymphatic system cancer	0.00175	0.0018	CcSEcCtD
Mefenamic acid—Confusional state—Bleomycin—lymphatic system cancer	0.00175	0.0018	CcSEcCtD
Mefenamic acid—Vision blurred—Carmustine—lymphatic system cancer	0.00175	0.0018	CcSEcCtD
Mefenamic acid—Tremor—Carmustine—lymphatic system cancer	0.00174	0.00179	CcSEcCtD
Mefenamic acid—Oedema—Bleomycin—lymphatic system cancer	0.00173	0.00179	CcSEcCtD
Mefenamic acid—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00173	0.00179	CcSEcCtD
Mefenamic acid—Infection—Bleomycin—lymphatic system cancer	0.00172	0.00178	CcSEcCtD
Mefenamic acid—Anaemia—Carmustine—lymphatic system cancer	0.00171	0.00177	CcSEcCtD
Mefenamic acid—Vomiting—Teniposide—lymphatic system cancer	0.00171	0.00176	CcSEcCtD
Mefenamic acid—Sepsis—Methotrexate—lymphatic system cancer	0.0017	0.00176	CcSEcCtD
Mefenamic acid—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.0017	0.00175	CcSEcCtD
Mefenamic acid—Asthenia—Fludarabine—lymphatic system cancer	0.0017	0.00175	CcSEcCtD
Mefenamic acid—Rash—Teniposide—lymphatic system cancer	0.0017	0.00175	CcSEcCtD
Mefenamic acid—Dermatitis—Teniposide—lymphatic system cancer	0.00169	0.00175	CcSEcCtD
Mefenamic acid—Headache—Teniposide—lymphatic system cancer	0.00169	0.00174	CcSEcCtD
Mefenamic acid—Pruritus—Fludarabine—lymphatic system cancer	0.00167	0.00173	CcSEcCtD
Mefenamic acid—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.00167	0.00172	CcSEcCtD
Mefenamic acid—Leukopenia—Carmustine—lymphatic system cancer	0.00166	0.00171	CcSEcCtD
Mefenamic acid—Anorexia—Bleomycin—lymphatic system cancer	0.00165	0.0017	CcSEcCtD
Mefenamic acid—Anaemia—Vincristine—lymphatic system cancer	0.00164	0.00169	CcSEcCtD
Mefenamic acid—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00162	0.00168	CcSEcCtD
Mefenamic acid—Photosensitivity—Methotrexate—lymphatic system cancer	0.00162	0.00168	CcSEcCtD
Mefenamic acid—Polyuria—Methotrexate—lymphatic system cancer	0.00162	0.00168	CcSEcCtD
Mefenamic acid—Hypotension—Bleomycin—lymphatic system cancer	0.00162	0.00167	CcSEcCtD
Mefenamic acid—Diarrhoea—Fludarabine—lymphatic system cancer	0.00162	0.00167	CcSEcCtD
Mefenamic acid—Convulsion—Carmustine—lymphatic system cancer	0.00161	0.00166	CcSEcCtD
Mefenamic acid—Hypertension—Carmustine—lymphatic system cancer	0.0016	0.00165	CcSEcCtD
Mefenamic acid—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.0016	0.00165	CcSEcCtD
Mefenamic acid—Nausea—Teniposide—lymphatic system cancer	0.0016	0.00165	CcSEcCtD
Mefenamic acid—Anaemia—Mitoxantrone—lymphatic system cancer	0.00159	0.00164	CcSEcCtD
Mefenamic acid—Vertigo—Vincristine—lymphatic system cancer	0.00159	0.00164	CcSEcCtD
Mefenamic acid—Hepatic failure—Methotrexate—lymphatic system cancer	0.00159	0.00164	CcSEcCtD
Mefenamic acid—Leukopenia—Vincristine—lymphatic system cancer	0.00158	0.00163	CcSEcCtD
Mefenamic acid—Anxiety—Carmustine—lymphatic system cancer	0.00157	0.00162	CcSEcCtD
Mefenamic acid—Paraesthesia—Bleomycin—lymphatic system cancer	0.00156	0.00161	CcSEcCtD
Mefenamic acid—Malaise—Mitoxantrone—lymphatic system cancer	0.00155	0.0016	CcSEcCtD
Mefenamic acid—Dyspnoea—Bleomycin—lymphatic system cancer	0.00155	0.00159	CcSEcCtD
Mefenamic acid—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00154	0.00159	CcSEcCtD
Mefenamic acid—Convulsion—Vincristine—lymphatic system cancer	0.00153	0.00158	CcSEcCtD
Mefenamic acid—Hypertension—Vincristine—lymphatic system cancer	0.00153	0.00158	CcSEcCtD
Mefenamic acid—Confusional state—Carmustine—lymphatic system cancer	0.00153	0.00157	CcSEcCtD
Mefenamic acid—Oedema—Carmustine—lymphatic system cancer	0.00151	0.00156	CcSEcCtD
Mefenamic acid—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.00151	0.00156	CcSEcCtD
Mefenamic acid—Decreased appetite—Bleomycin—lymphatic system cancer	0.00151	0.00155	CcSEcCtD
Mefenamic acid—Infection—Carmustine—lymphatic system cancer	0.0015	0.00155	CcSEcCtD
Mefenamic acid—Vomiting—Fludarabine—lymphatic system cancer	0.0015	0.00155	CcSEcCtD
Mefenamic acid—Convulsion—Mitoxantrone—lymphatic system cancer	0.00149	0.00154	CcSEcCtD
Mefenamic acid—Rash—Fludarabine—lymphatic system cancer	0.00149	0.00154	CcSEcCtD
Mefenamic acid—Dermatitis—Fludarabine—lymphatic system cancer	0.00149	0.00154	CcSEcCtD
Mefenamic acid—Hypertension—Mitoxantrone—lymphatic system cancer	0.00149	0.00153	CcSEcCtD
Mefenamic acid—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00148	0.00153	CcSEcCtD
Mefenamic acid—Headache—Fludarabine—lymphatic system cancer	0.00148	0.00153	CcSEcCtD
Mefenamic acid—Tachycardia—Carmustine—lymphatic system cancer	0.00148	0.00152	CcSEcCtD
Mefenamic acid—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00147	0.00152	CcSEcCtD
Mefenamic acid—Anxiety—Mitoxantrone—lymphatic system cancer	0.00146	0.00151	CcSEcCtD
Mefenamic acid—Discomfort—Mitoxantrone—lymphatic system cancer	0.00145	0.0015	CcSEcCtD
Mefenamic acid—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00144	0.00149	CcSEcCtD
Mefenamic acid—Oedema—Vincristine—lymphatic system cancer	0.00144	0.00149	CcSEcCtD
Mefenamic acid—Anorexia—Carmustine—lymphatic system cancer	0.00144	0.00149	CcSEcCtD
Mefenamic acid—Infection—Vincristine—lymphatic system cancer	0.00144	0.00148	CcSEcCtD
Mefenamic acid—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00143	0.00147	CcSEcCtD
Mefenamic acid—Confusional state—Mitoxantrone—lymphatic system cancer	0.00142	0.00146	CcSEcCtD
Mefenamic acid—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00141	0.00146	CcSEcCtD
Mefenamic acid—Hypotension—Carmustine—lymphatic system cancer	0.00141	0.00146	CcSEcCtD
Mefenamic acid—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00141	0.00145	CcSEcCtD
Mefenamic acid—Oedema—Mitoxantrone—lymphatic system cancer	0.00141	0.00145	CcSEcCtD
Mefenamic acid—Nausea—Fludarabine—lymphatic system cancer	0.0014	0.00145	CcSEcCtD
Mefenamic acid—Infection—Mitoxantrone—lymphatic system cancer	0.0014	0.00144	CcSEcCtD
Mefenamic acid—Shock—Mitoxantrone—lymphatic system cancer	0.00138	0.00143	CcSEcCtD
Mefenamic acid—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00138	0.00142	CcSEcCtD
Mefenamic acid—Urticaria—Bleomycin—lymphatic system cancer	0.00138	0.00142	CcSEcCtD
Mefenamic acid—Anorexia—Vincristine—lymphatic system cancer	0.00138	0.00142	CcSEcCtD
Mefenamic acid—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00137	0.00142	CcSEcCtD
Mefenamic acid—Body temperature increased—Bleomycin—lymphatic system cancer	0.00137	0.00141	CcSEcCtD
Mefenamic acid—Insomnia—Carmustine—lymphatic system cancer	0.00137	0.00141	CcSEcCtD
Mefenamic acid—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00137	0.00141	CcSEcCtD
Mefenamic acid—Paraesthesia—Carmustine—lymphatic system cancer	0.00136	0.0014	CcSEcCtD
Mefenamic acid—Hypotension—Vincristine—lymphatic system cancer	0.00135	0.00139	CcSEcCtD
Mefenamic acid—Dyspnoea—Carmustine—lymphatic system cancer	0.00135	0.00139	CcSEcCtD
Mefenamic acid—Somnolence—Carmustine—lymphatic system cancer	0.00135	0.00139	CcSEcCtD
Mefenamic acid—Anorexia—Mitoxantrone—lymphatic system cancer	0.00134	0.00138	CcSEcCtD
Mefenamic acid—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.00132	0.00136	CcSEcCtD
Mefenamic acid—Decreased appetite—Carmustine—lymphatic system cancer	0.00132	0.00136	CcSEcCtD
Mefenamic acid—Hypotension—Mitoxantrone—lymphatic system cancer	0.00131	0.00136	CcSEcCtD
Mefenamic acid—Insomnia—Vincristine—lymphatic system cancer	0.00131	0.00135	CcSEcCtD
Mefenamic acid—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00131	0.00135	CcSEcCtD
Mefenamic acid—Paraesthesia—Vincristine—lymphatic system cancer	0.0013	0.00134	CcSEcCtD
Mefenamic acid—Constipation—Carmustine—lymphatic system cancer	0.00129	0.00133	CcSEcCtD
Mefenamic acid—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00128	0.00132	CcSEcCtD
Mefenamic acid—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00126	0.0013	CcSEcCtD
Mefenamic acid—Decreased appetite—Vincristine—lymphatic system cancer	0.00126	0.0013	CcSEcCtD
Mefenamic acid—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00125	0.00129	CcSEcCtD
Mefenamic acid—Somnolence—Mitoxantrone—lymphatic system cancer	0.00125	0.00129	CcSEcCtD
Mefenamic acid—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00125	0.00129	CcSEcCtD
Mefenamic acid—Feeling abnormal—Carmustine—lymphatic system cancer	0.00125	0.00129	CcSEcCtD
Mefenamic acid—Asthenia—Bleomycin—lymphatic system cancer	0.00124	0.00128	CcSEcCtD
Mefenamic acid—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00124	0.00128	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00124	0.00128	CcSEcCtD
Mefenamic acid—Constipation—Vincristine—lymphatic system cancer	0.00124	0.00127	CcSEcCtD
Mefenamic acid—Asthma—Methotrexate—lymphatic system cancer	0.00123	0.00127	CcSEcCtD
Mefenamic acid—Pruritus—Bleomycin—lymphatic system cancer	0.00123	0.00126	CcSEcCtD
Mefenamic acid—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00122	0.00126	CcSEcCtD
Mefenamic acid—Eosinophilia—Methotrexate—lymphatic system cancer	0.00122	0.00126	CcSEcCtD
Mefenamic acid—Pancreatitis—Methotrexate—lymphatic system cancer	0.00121	0.00125	CcSEcCtD
Mefenamic acid—Constipation—Mitoxantrone—lymphatic system cancer	0.0012	0.00124	CcSEcCtD
Mefenamic acid—Abdominal pain—Carmustine—lymphatic system cancer	0.0012	0.00123	CcSEcCtD
Mefenamic acid—Body temperature increased—Carmustine—lymphatic system cancer	0.0012	0.00123	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00118	0.00122	CcSEcCtD
Mefenamic acid—Pancytopenia—Methotrexate—lymphatic system cancer	0.00117	0.00121	CcSEcCtD
Mefenamic acid—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00116	0.0012	CcSEcCtD
Mefenamic acid—Dysuria—Methotrexate—lymphatic system cancer	0.00115	0.00119	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00115	0.00119	CcSEcCtD
Mefenamic acid—Abdominal pain—Vincristine—lymphatic system cancer	0.00114	0.00118	CcSEcCtD
Mefenamic acid—Body temperature increased—Vincristine—lymphatic system cancer	0.00114	0.00118	CcSEcCtD
Mefenamic acid—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00112	0.00116	CcSEcCtD
Mefenamic acid—Urticaria—Mitoxantrone—lymphatic system cancer	0.00112	0.00115	CcSEcCtD
Mefenamic acid—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00111	0.00115	CcSEcCtD
Mefenamic acid—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00111	0.00115	CcSEcCtD
Mefenamic acid—Pneumonia—Methotrexate—lymphatic system cancer	0.00111	0.00114	CcSEcCtD
Mefenamic acid—Vomiting—Bleomycin—lymphatic system cancer	0.0011	0.00114	CcSEcCtD
Mefenamic acid—Drowsiness—Methotrexate—lymphatic system cancer	0.0011	0.00113	CcSEcCtD
Mefenamic acid—Rash—Bleomycin—lymphatic system cancer	0.00109	0.00113	CcSEcCtD
Mefenamic acid—Dermatitis—Bleomycin—lymphatic system cancer	0.00109	0.00113	CcSEcCtD
Mefenamic acid—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00109	0.00112	CcSEcCtD
Mefenamic acid—Asthenia—Carmustine—lymphatic system cancer	0.00109	0.00112	CcSEcCtD
Mefenamic acid—Renal failure—Methotrexate—lymphatic system cancer	0.00108	0.00111	CcSEcCtD
Mefenamic acid—Stomatitis—Methotrexate—lymphatic system cancer	0.00107	0.0011	CcSEcCtD
Mefenamic acid—Conjunctivitis—Methotrexate—lymphatic system cancer	0.00107	0.0011	CcSEcCtD
Mefenamic acid—Haematuria—Methotrexate—lymphatic system cancer	0.00105	0.00108	CcSEcCtD
Mefenamic acid—Asthenia—Vincristine—lymphatic system cancer	0.00104	0.00107	CcSEcCtD
Mefenamic acid—Diarrhoea—Carmustine—lymphatic system cancer	0.00104	0.00107	CcSEcCtD
Mefenamic acid—Nausea—Bleomycin—lymphatic system cancer	0.00103	0.00106	CcSEcCtD
Mefenamic acid—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00103	0.00106	CcSEcCtD
Mefenamic acid—Asthenia—Mitoxantrone—lymphatic system cancer	0.00101	0.00104	CcSEcCtD
Mefenamic acid—Dizziness—Carmustine—lymphatic system cancer	0.001	0.00103	CcSEcCtD
Mefenamic acid—Haemoglobin—Methotrexate—lymphatic system cancer	0.000992	0.00102	CcSEcCtD
Mefenamic acid—Diarrhoea—Vincristine—lymphatic system cancer	0.000988	0.00102	CcSEcCtD
Mefenamic acid—Hepatitis—Methotrexate—lymphatic system cancer	0.000987	0.00102	CcSEcCtD
Mefenamic acid—Haemorrhage—Methotrexate—lymphatic system cancer	0.000987	0.00102	CcSEcCtD
Mefenamic acid—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000974	0.001	CcSEcCtD
Mefenamic acid—Urethral disorder—Methotrexate—lymphatic system cancer	0.000967	0.000997	CcSEcCtD
Mefenamic acid—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000962	0.000993	CcSEcCtD
Mefenamic acid—Vomiting—Carmustine—lymphatic system cancer	0.000962	0.000992	CcSEcCtD
Mefenamic acid—Dizziness—Vincristine—lymphatic system cancer	0.000955	0.000985	CcSEcCtD
Mefenamic acid—Rash—Carmustine—lymphatic system cancer	0.000954	0.000984	CcSEcCtD
Mefenamic acid—Dermatitis—Carmustine—lymphatic system cancer	0.000953	0.000983	CcSEcCtD
Mefenamic acid—Headache—Carmustine—lymphatic system cancer	0.000948	0.000978	CcSEcCtD
Mefenamic acid—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000933	0.000962	CcSEcCtD
Mefenamic acid—Tinnitus—Methotrexate—lymphatic system cancer	0.00092	0.000949	CcSEcCtD
Mefenamic acid—Vomiting—Vincristine—lymphatic system cancer	0.000918	0.000947	CcSEcCtD
Mefenamic acid—Rash—Vincristine—lymphatic system cancer	0.000911	0.000939	CcSEcCtD
Mefenamic acid—Dermatitis—Vincristine—lymphatic system cancer	0.00091	0.000938	CcSEcCtD
Mefenamic acid—Headache—Vincristine—lymphatic system cancer	0.000905	0.000933	CcSEcCtD
Mefenamic acid—Nausea—Carmustine—lymphatic system cancer	0.000899	0.000927	CcSEcCtD
Mefenamic acid—Vomiting—Mitoxantrone—lymphatic system cancer	0.000894	0.000923	CcSEcCtD
Mefenamic acid—Rash—Mitoxantrone—lymphatic system cancer	0.000887	0.000915	CcSEcCtD
Mefenamic acid—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000886	0.000914	CcSEcCtD
Mefenamic acid—Headache—Mitoxantrone—lymphatic system cancer	0.000881	0.000909	CcSEcCtD
Mefenamic acid—Alopecia—Methotrexate—lymphatic system cancer	0.000872	0.000899	CcSEcCtD
Mefenamic acid—Mental disorder—Methotrexate—lymphatic system cancer	0.000864	0.000891	CcSEcCtD
Mefenamic acid—Nausea—Vincristine—lymphatic system cancer	0.000858	0.000885	CcSEcCtD
Mefenamic acid—Nausea—Mitoxantrone—lymphatic system cancer	0.000836	0.000862	CcSEcCtD
Mefenamic acid—Vision blurred—Methotrexate—lymphatic system cancer	0.000809	0.000835	CcSEcCtD
Mefenamic acid—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000797	0.000822	CcSEcCtD
Mefenamic acid—Anaemia—Methotrexate—lymphatic system cancer	0.000794	0.000819	CcSEcCtD
Mefenamic acid—Malaise—Methotrexate—lymphatic system cancer	0.000774	0.000799	CcSEcCtD
Mefenamic acid—Vertigo—Methotrexate—lymphatic system cancer	0.000772	0.000796	CcSEcCtD
Mefenamic acid—Leukopenia—Methotrexate—lymphatic system cancer	0.000769	0.000793	CcSEcCtD
Mefenamic acid—Convulsion—Methotrexate—lymphatic system cancer	0.000744	0.000767	CcSEcCtD
Mefenamic acid—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000726	0.000749	CcSEcCtD
Mefenamic acid—Discomfort—Methotrexate—lymphatic system cancer	0.000722	0.000745	CcSEcCtD
Mefenamic acid—Confusional state—Methotrexate—lymphatic system cancer	0.000707	0.000729	CcSEcCtD
Mefenamic acid—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000701	0.000723	CcSEcCtD
Mefenamic acid—Infection—Methotrexate—lymphatic system cancer	0.000696	0.000718	CcSEcCtD
Mefenamic acid—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000686	0.000708	CcSEcCtD
Mefenamic acid—Skin disorder—Methotrexate—lymphatic system cancer	0.000681	0.000702	CcSEcCtD
Mefenamic acid—Anorexia—Methotrexate—lymphatic system cancer	0.000668	0.000689	CcSEcCtD
Mefenamic acid—Hypotension—Methotrexate—lymphatic system cancer	0.000655	0.000675	CcSEcCtD
Mefenamic acid—Insomnia—Methotrexate—lymphatic system cancer	0.000634	0.000654	CcSEcCtD
Mefenamic acid—Paraesthesia—Methotrexate—lymphatic system cancer	0.000629	0.000649	CcSEcCtD
Mefenamic acid—Dyspnoea—Methotrexate—lymphatic system cancer	0.000625	0.000644	CcSEcCtD
Mefenamic acid—Somnolence—Methotrexate—lymphatic system cancer	0.000623	0.000643	CcSEcCtD
Mefenamic acid—Dyspepsia—Methotrexate—lymphatic system cancer	0.000617	0.000636	CcSEcCtD
Mefenamic acid—Decreased appetite—Methotrexate—lymphatic system cancer	0.000609	0.000628	CcSEcCtD
Mefenamic acid—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000605	0.000624	CcSEcCtD
Mefenamic acid—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000578	0.000596	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000573	0.000591	CcSEcCtD
Mefenamic acid—Urticaria—Methotrexate—lymphatic system cancer	0.000557	0.000574	CcSEcCtD
Mefenamic acid—Abdominal pain—Methotrexate—lymphatic system cancer	0.000554	0.000571	CcSEcCtD
Mefenamic acid—Body temperature increased—Methotrexate—lymphatic system cancer	0.000554	0.000571	CcSEcCtD
Mefenamic acid—Asthenia—Methotrexate—lymphatic system cancer	0.000503	0.000519	CcSEcCtD
Mefenamic acid—Pruritus—Methotrexate—lymphatic system cancer	0.000496	0.000511	CcSEcCtD
Mefenamic acid—Diarrhoea—Methotrexate—lymphatic system cancer	0.00048	0.000495	CcSEcCtD
Mefenamic acid—Dizziness—Methotrexate—lymphatic system cancer	0.000463	0.000478	CcSEcCtD
Mefenamic acid—Vomiting—Methotrexate—lymphatic system cancer	0.000446	0.00046	CcSEcCtD
Mefenamic acid—Rash—Methotrexate—lymphatic system cancer	0.000442	0.000456	CcSEcCtD
Mefenamic acid—Dermatitis—Methotrexate—lymphatic system cancer	0.000442	0.000455	CcSEcCtD
Mefenamic acid—Headache—Methotrexate—lymphatic system cancer	0.000439	0.000453	CcSEcCtD
Mefenamic acid—Nausea—Methotrexate—lymphatic system cancer	0.000416	0.000429	CcSEcCtD
